Skip to content

Why Is Canada’s Approval Of Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) Important ? : SeekingAlpha.com Perspective

December 4, 2012

       SeekingAlpha.com’s December 3, 2012 article titled, “Kalydeco Approval In Canada More Important To Patients Than To Vertex”, is an interesting perspective on why Health Canada’s approval of Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) for Cystic Fibrosis is more important to the patient than to the company.  

 Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: